uracil has been researched along with Asthenia in 4 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 9.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "We investigated the efficacy and safety of oral Uracil/tegafur (UFT) with leucovorin and mitomycin C (MMC) as third-line treatment for patients with extensively pretreated metastatic colorectal cancer (mCRC)." | 5.16 | Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. ( Chamorey, E; Dahan, L; Evesque, L; Follana, P; Francois, E; Mari, V; Michel, C; Perrier, H; Seitz, JF; Smith, D, 2012) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Francois, E | 1 |
| Smith, D | 1 |
| Dahan, L | 1 |
| Michel, C | 1 |
| Perrier, H | 1 |
| Mari, V | 1 |
| Seitz, JF | 1 |
| Follana, P | 1 |
| Evesque, L | 1 |
| Chamorey, E | 1 |
| Hong, DS | 1 |
| Abbruzzese, JL | 1 |
| Bogaard, K | 1 |
| Lassere, Y | 1 |
| Fukushima, M | 1 |
| Mita, A | 1 |
| Kuwata, K | 1 |
| Hoff, PM | 1 |
| Daniels, M | 1 |
| Díaz-Rubio, E | 1 |
| Guillem, V | 1 |
| Montero, JM | 1 |
| García-Conde, J | 1 |
| Estapé, J | 1 |
| Martín, M | 1 |
| Herranz, C | 1 |
| Ordoñez, A | 1 |
| Galán, A | 1 |
| Lomazova, MM | 1 |
3 trials available for uracil and Asthenia
| Article | Year |
|---|---|
Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2012 |
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
Phase II trial of UFT activity in pretreated breast cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; A | 1993 |
1 other study available for uracil and Asthenia
| Article | Year |
|---|---|
[Treatment of ulcer disease and asthenic-depressive syndrome with methyluracil].
Topics: Adult; Asthenia; Depression; Duodenal Ulcer; Female; Humans; Syndrome; Uracil | 1974 |